Windlas Biotech Limited has announced a Board of Directors meeting scheduled for April 17, 2026, to consider a significant corporate action involving the buyback of its equity shares. The pharmaceutical company has informed stock exchanges about this development through a formal communication dated April 14, 2026.

Board Meeting Details

The upcoming board meeting will focus on a comprehensive review and approval of the share buyback proposal. The company has outlined the key aspects of this corporate action in its regulatory filing.

Regulatory Compliance Framework

The proposed buyback will be conducted in strict adherence to multiple regulatory requirements. The company has emphasized compliance with the Companies Act, 2013, including rules framed thereunder, and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended. All matters necessary and incidental to the buyback process will be addressed during the board deliberations.

Trading Window Restrictions

Windlas Biotech has implemented trading restrictions for designated persons as part of its insider trading prevention measures. The company has provided specific details regarding the current trading window closure.

These restrictions are implemented pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring & Reporting of Trading.

Corporate Communication

The announcement was made through official communications to both major stock exchanges where the company's shares are listed. Windlas Biotech has requested the exchanges to take this information on record, ensuring transparency and regulatory compliance in its corporate actions.

Windlas biotech Limited has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE and NSE on April 6, 2026.

Quarterly Compliance Certificate Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The document pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Key Confirmation

MUFG Intime India Private Limited confirmed that during the quarter ended March 31, 2026, no demat requests were received for processing. The registrar specifically noted that Windlas Biotech Limited does not have any physical shares outstanding, indicating that all shares are already in dematerialized form.

Regulatory Compliance

The submission was made to the compliance departments of both major Indian stock exchanges. Company Secretary and Compliance Officer Ananta Narayan Panda signed the filing letter, ensuring adherence to regulatory requirements. This quarterly certificate filing is a standard compliance requirement for listed companies under SEBI regulations.

Company Information

Windlas Biotech Limited operates from its registered office in Dehradun, Uttarakhand, with its corporate office located in Gurgaon, Haryana. The company maintains its listing on both BSE and NSE, trading under the symbols 543329 and WINDLAS respectively.